1. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Issue 2 (4th August 2020) Authors: Alessi, Joao V; Ricciuti, Biagio; Jiménez-Aguilar, Elizabeth; Hong, Fangxin; Wei, Zihan; Nishino, Mizuki; Plodkowski, Andrew J; Sawan, Peter; Luo, Jia; Rizvi, Hira; Carter, Brett W; Heymach, John V; Altan, Mehmet; Hellmann, Matthew; Awad, Mark Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Type A thymoma presenting with bone metastasis. Issue 4 (8th July 2018) Authors: Montecalvo, Joseph; Chang, Jason; Rekhtman, Natasha; Antonescu, Cristina R; Bains, Manjit S; Fabbri, Nicola; Plodkowski, Andrew J; Riely, Gregory J; Travis, William D; Sauter, Jennifer L Journal: Histopathology Issue: Volume 73:Issue 4(2019) Page Start: 701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗